- SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1
- QALSODY is Biogen's third rare disease therapy to be approved in the EU, demonstrating the company's commitment to addressing diseases with a high unmet need
- With QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field
Biogen Announces European Commission Grants Marketing Authorization For QALSODY To Treat SOD1-ALS In Adults; Maintains Orphan Designation
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.